Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

Silvia Minozzi, S. Bonovas, Theodore Lytras, Valentina Pecoraro, M. González-Lorenzo, Anan Judina Bastiampillai, Eugenia Maria Gabrielli, Carlo Andrea Lonati, Pasquale Lorenzo Moja, M. Cinquini, V. Marino, Andrea Matucci, G.M. Milano, G. Tocci, R. Scarpa, D. Goletti, F. Cantini

Research output: Contribution to journalArticle

Abstract

INTRODUCTION:

Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection). We searched Medline, Embase, and the Cochrane Library up to May 2014 to identify eligible studies in adult patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis that evaluated anti-TNF drugs compared with placebo or no treatment. Expert opinion: Our study encompassed data from 71 randomized controlled trials involving 22,760 participants (range of follow-up: 1-36 months) and seven open label extension studies with 2,236 participants (range of follow-up: 6-48 months). Quantitative synthesis of the available data found statistically significant increases in the occurrence of any infections (20%), serious infections (40%), and tuberculosis (250%) associated with anti-TNF drug use, while the data for opportunistic infections were scarce. The quality of synthesized evidence was judged as moderate. Further evidence from registries and long-term epidemiological studies are needed to better define the relationship between anti-TNF agents and infection complications.
Original languageItalian
Pages (from-to)11-34
Number of pages24
JournalExpert Opinion on Drug Safety
Volume15
Issue numbersup 1
Publication statusPublished - Dec 2016

Cite this

Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., ... Cantini, F. (2016). Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 15(sup 1), 11-34.

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. / Minozzi, Silvia; Bonovas, S.; Lytras, Theodore; Pecoraro, Valentina; González-Lorenzo, M.; Bastiampillai, Anan Judina; Gabrielli, Eugenia Maria; Lonati, Carlo Andrea; Moja, Pasquale Lorenzo; Cinquini, M.; Marino, V.; Matucci, Andrea; Milano, G.M.; Tocci, G.; Scarpa, R.; Goletti, D.; Cantini, F.

In: Expert Opinion on Drug Safety, Vol. 15, No. sup 1, 12.2016, p. 11-34.

Research output: Contribution to journalArticle

Minozzi, S, Bonovas, S, Lytras, T, Pecoraro, V, González-Lorenzo, M, Bastiampillai, AJ, Gabrielli, EM, Lonati, CA, Moja, PL, Cinquini, M, Marino, V, Matucci, A, Milano, GM, Tocci, G, Scarpa, R, Goletti, D & Cantini, F 2016, 'Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis', Expert Opinion on Drug Safety, vol. 15, no. sup 1, pp. 11-34.
Minozzi, Silvia ; Bonovas, S. ; Lytras, Theodore ; Pecoraro, Valentina ; González-Lorenzo, M. ; Bastiampillai, Anan Judina ; Gabrielli, Eugenia Maria ; Lonati, Carlo Andrea ; Moja, Pasquale Lorenzo ; Cinquini, M. ; Marino, V. ; Matucci, Andrea ; Milano, G.M. ; Tocci, G. ; Scarpa, R. ; Goletti, D. ; Cantini, F. / Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. In: Expert Opinion on Drug Safety. 2016 ; Vol. 15, No. sup 1. pp. 11-34.
@article{907995eccec64e4db4b7ce7c4563e04b,
title = "Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis",
abstract = "INTRODUCTION:Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection). We searched Medline, Embase, and the Cochrane Library up to May 2014 to identify eligible studies in adult patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis that evaluated anti-TNF drugs compared with placebo or no treatment. Expert opinion: Our study encompassed data from 71 randomized controlled trials involving 22,760 participants (range of follow-up: 1-36 months) and seven open label extension studies with 2,236 participants (range of follow-up: 6-48 months). Quantitative synthesis of the available data found statistically significant increases in the occurrence of any infections (20{\%}), serious infections (40{\%}), and tuberculosis (250{\%}) associated with anti-TNF drug use, while the data for opportunistic infections were scarce. The quality of synthesized evidence was judged as moderate. Further evidence from registries and long-term epidemiological studies are needed to better define the relationship between anti-TNF agents and infection complications.",
author = "Silvia Minozzi and S. Bonovas and Theodore Lytras and Valentina Pecoraro and M. Gonz{\'a}lez-Lorenzo and Bastiampillai, {Anan Judina} and Gabrielli, {Eugenia Maria} and Lonati, {Carlo Andrea} and Moja, {Pasquale Lorenzo} and M. Cinquini and V. Marino and Andrea Matucci and G.M. Milano and G. Tocci and R. Scarpa and D. Goletti and F. Cantini",
note = "Export Date: 31 March 2017",
year = "2016",
month = "12",
language = "Italian",
volume = "15",
pages = "11--34",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "sup 1",

}

TY - JOUR

T1 - Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis

AU - Minozzi, Silvia

AU - Bonovas, S.

AU - Lytras, Theodore

AU - Pecoraro, Valentina

AU - González-Lorenzo, M.

AU - Bastiampillai, Anan Judina

AU - Gabrielli, Eugenia Maria

AU - Lonati, Carlo Andrea

AU - Moja, Pasquale Lorenzo

AU - Cinquini, M.

AU - Marino, V.

AU - Matucci, Andrea

AU - Milano, G.M.

AU - Tocci, G.

AU - Scarpa, R.

AU - Goletti, D.

AU - Cantini, F.

N1 - Export Date: 31 March 2017

PY - 2016/12

Y1 - 2016/12

N2 - INTRODUCTION:Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection). We searched Medline, Embase, and the Cochrane Library up to May 2014 to identify eligible studies in adult patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis that evaluated anti-TNF drugs compared with placebo or no treatment. Expert opinion: Our study encompassed data from 71 randomized controlled trials involving 22,760 participants (range of follow-up: 1-36 months) and seven open label extension studies with 2,236 participants (range of follow-up: 6-48 months). Quantitative synthesis of the available data found statistically significant increases in the occurrence of any infections (20%), serious infections (40%), and tuberculosis (250%) associated with anti-TNF drug use, while the data for opportunistic infections were scarce. The quality of synthesized evidence was judged as moderate. Further evidence from registries and long-term epidemiological studies are needed to better define the relationship between anti-TNF agents and infection complications.

AB - INTRODUCTION:Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection). We searched Medline, Embase, and the Cochrane Library up to May 2014 to identify eligible studies in adult patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis that evaluated anti-TNF drugs compared with placebo or no treatment. Expert opinion: Our study encompassed data from 71 randomized controlled trials involving 22,760 participants (range of follow-up: 1-36 months) and seven open label extension studies with 2,236 participants (range of follow-up: 6-48 months). Quantitative synthesis of the available data found statistically significant increases in the occurrence of any infections (20%), serious infections (40%), and tuberculosis (250%) associated with anti-TNF drug use, while the data for opportunistic infections were scarce. The quality of synthesized evidence was judged as moderate. Further evidence from registries and long-term epidemiological studies are needed to better define the relationship between anti-TNF agents and infection complications.

M3 - Articolo

VL - 15

SP - 11

EP - 34

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - sup 1

ER -